AWM
UTHR icon

Apollon Wealth Management’s United Therapeutics UTHR Stock Holding History

Apollon Wealth Management’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$12.2M Buy
22,585
+9,297
+70% +$5.24M 0.15% 134
2026
Q1 		$7.88M Buy
+13,288
New +$6.62M 0.13% 149

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM

Apollon Wealth Management's UTHR Position: Q2 2026 in Review

Apollon Wealth Management increased its United Therapeutics (UTHR) stake by 70% in Q2 2026, buying an estimated $5.24M and bringing the position to 22,585 shares worth $12.2M. The position accounts for 0.15% of the portfolio, ranked #134.

Apollon Wealth Management first reported a position in UTHR in Q1 2026 and has held it in 2 quarters since. 880 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

  • Apollon Wealth Management held 22,585 shares of United Therapeutics worth $12.2M as of Q2 2026.
  • Apollon Wealth Management bought 9,297 United Therapeutics shares in Q2 2026, an estimated $5.24M.
  • United Therapeutics made up 0.15% of Apollon Wealth Management's portfolio in Q2 2026, its #134 holding.
  • Apollon Wealth Management first reported a position in United Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 880 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on Apollon Wealth Management's 13F filing for Q2 2026, filed 23 Jul 2026.